July 17, 2015.
Valeant Pharmaceuticals has entered into an agreement to acquire Mercury (Cayman) Holdings, the holding company of Egypt's Amoun Pharmaceutical, for approximately US$800 million, plus contingent payments.
Amoun Pharmaceutical is the largest domestic company in the Egyptian pharmaceutical market with annual growth of approximately 20%. The company operates one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East. It produces market-leading pharmaceutical brands in the anti-hypertensive, broad spectrum antibiotic and anti-diarrheal areas.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.